Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibecotamab for MRD-Positive AML and MDS After HMA Failure
NCT05285813Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vibecotamab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started May 2022; status: terminated.
02
Drugs
vibecotamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05285813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285813.